PrandiMet FDA Approval History
FDA Approved: Yes (Discontinued) (First approved June 23, 2008)
Brand name: PrandiMet
Generic name: repaglinide and metformin
Dosage form: Tablets
Company: Novo Nordisk
Treatment for: Diabetes, Type 2
Marketing Status: Discontinued
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.
Development timeline for PrandiMet
| Date | Article |
|---|---|
| Jun 24, 2008 | Approval FDA Approves PrandiMet, a Replaglinide and Metformin Fixed-Dose Combination Tablet for Treatment of Type 2 Diabetes |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
